Literature DB >> 18515975

Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study.

P J Visser1, F R J Verhey, M Boada, R Bullock, P P De Deyn, G B Frisoni, L Frolich, H Hampel, J Jolles, R Jones, L Minthon, F Nobili, M Olde Rikkert, P-J Ousset, A-S Rigaud, P Scheltens, H Soininen, L Spiru, J Touchon, M Tsolaki, B Vellas, L-O Wahlund, G Wilcock, B Winblad.   

Abstract

BACKGROUND: There is an urgent need to identify subjects with Alzheimer's disease (AD) in the predementia phase, but validated diagnostic approaches are currently lacking. In this paper, we present the background, design and methods of a study, which aims to develop clinical criteria for predementia AD. We also present baseline characteristics of the subjects included. The study was part of the multicentre DESCRIPA project, which is being conducted within the network of the European Alzheimer's Disease Consortium.
METHODS: Clinical criteria will be based on a prospective cohort study of non-demented subjects older than 55 years and referred to a memory clinic. At baseline, a number of markers and risk factors for AD were collected, including demographic variables, measures of performance in activities of daily living, cognitive, neuroimaging and genetic markers, and serum and cerebrospinal fluid markers. Subjects will be reassessed annually for 2-3 years, and we will evaluate which combination of variables best predicts AD-type dementia at follow-up.
RESULTS: Between 2003 and 2005, 881 subjects were included from 20 memory clinics. Subjects were on average 70.3 years old, and had 10.4 years of education. The average score on the Mini-Mental State Examination was 27.4. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18515975      PMCID: PMC2821431          DOI: 10.1159/000135644

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  55 in total

1.  Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets.

Authors:  E W Steyerberg; M J Eijkemans; F E Harrell; J D Habbema
Journal:  Stat Med       Date:  2000-04-30       Impact factor: 2.373

Review 2.  Clinical trials in mild cognitive impairment: lessons for the future.

Authors:  V Jelic; M Kivipelto; B Winblad
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

3.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  Screening for dementia by memory testing.

Authors:  E Grober; H Buschke; H Crystal; S Bang; R Dresner
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

5.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

Review 7.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

8.  Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

Authors:  R S Bucks; D L Ashworth; G K Wilcock; K Siegfried
Journal:  Age Ageing       Date:  1996-03       Impact factor: 10.668

9.  Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Authors:  D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910

10.  The Bayer Activities of Daily Living Scale (B-ADL).

Authors:  I Hindmarch; H Lehfeld; P de Jongh; H Erzigkeit
Journal:  Dement Geriatr Cogn Disord       Date:  1998       Impact factor: 2.959

View more
  25 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

3.  Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

Authors:  Joan Hq Shen; Qi Shen; Holly Yu; Jin-Shei Lai; Jennifer L Beaumont; Zhenxin Zhang; Huali Wang; Seong Yoon Kim; Christopher Chen; Timothy Kwok; Shuu-Jiun Wang; Dong Young Lee; John Harrison; Jeffrey Cummings
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

Review 4.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

5.  Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Authors:  Rosalinde E R Slot; Sietske A M Sikkes; Johannes Berkhof; Henry Brodaty; Rachel Buckley; Enrica Cavedo; Efthimios Dardiotis; Francoise Guillo-Benarous; Harald Hampel; Nicole A Kochan; Simone Lista; Tobias Luck; Paul Maruff; José Luis Molinuevo; Johannes Kornhuber; Barry Reisberg; Steffi G Riedel-Heller; Shannon L Risacher; Susanne Roehr; Perminder S Sachdev; Nikolaos Scarmeas; Philip Scheltens; Melanie B Shulman; Andrew J Saykin; Sander C J Verfaillie; Pieter Jelle Visser; Stephanie J B Vos; Michael Wagner; Steffen Wolfsgruber; Frank Jessen; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

6.  Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study.

Authors:  Silvia Morbelli; Arnoldo Piccardo; Giampiero Villavecchia; Barbara Dessi; Andrea Brugnolo; Alessandra Piccini; Anna Caroli; Giovanni Frisoni; Guido Rodriguez; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

Authors:  Ineke A van Rossum; Stephanie J B Vos; Leah Burns; Dirk L Knol; Philip Scheltens; Hilkka Soininen; Lars-Olof Wahlund; Harald Hampel; Magda Tsolaki; Lennart Minthon; Gilbert L'italien; Wiesje M van der Flier; Charlotte E Teunissen; Kaj Blennow; Frederik Barkhof; Daniel Rueckert; Robin Wolz; Frans Verhey; Pieter Jelle Visser
Journal:  Neurology       Date:  2012-09-26       Impact factor: 9.910

8.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

Authors:  Stephanie J B Vos; Frans Verhey; Lutz Frölich; Johannes Kornhuber; Jens Wiltfang; Wolfgang Maier; Oliver Peters; Eckart Rüther; Flavio Nobili; Silvia Morbelli; Giovanni B Frisoni; Alexander Drzezga; Mira Didic; Bart N M van Berckel; Andrew Simmons; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Muscio; Sanna-Kaisa Herukka; Eric Salmon; Christine Bastin; Anders Wallin; Arto Nordlund; Alexandre de Mendonça; Dina Silva; Isabel Santana; Raquel Lemos; Sebastiaan Engelborghs; Stefan Van der Mussele; Yvonne Freund-Levi; Åsa K Wallin; Harald Hampel; Wiesje van der Flier; Philip Scheltens; Pieter Jelle Visser
Journal:  Brain       Date:  2015-02-17       Impact factor: 13.501

9.  Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.

Authors:  I H G B Ramakers; F R J Verhey; P Scheltens; H Hampel; H Soininen; P Aalten; M Olde Rikkert; M M Verbeek; L Spiru; K Blennow; J Q Trojanowski; L M Shaw; P J Visser
Journal:  Psychol Med       Date:  2012-09-07       Impact factor: 7.723

10.  Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study.

Authors:  Ron L H Handels; Pauline Aalten; Claire A G Wolfs; Marcel OldeRikkert; Philip Scheltens; Pieter Jelle Visser; Manuela A Joore; Johan L Severens; Frans R J Verhey
Journal:  BMC Neurol       Date:  2012-08-10       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.